Skip to main content

Table 3 Cobimetinib dose modification after the first event of serous retinopathy in the cobimetinib plus vemurafenib arm

From: Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study

Action taken with cobimetinib All patients with serous retinopathy events (n = 63) Patients with grade 1 events (n = 36) Patients with grade 2 events (n = 20) Patients with grade 3 events (n = 6) Patients with grade 4 events (n = 1)
All Resolved All Resolved All Resolved All Resolved All Resolved
Dose not changed, n 30 12 26 10 3 1 1 1 0 0
Dose reduced, n 18 16 4 3 13 12 1 1 0 0
Drug interrupted, n 10 5 5 3 2 0 3 2 0 0
Drug withdrawn, n 4 1 0 0 2 1 1a 0 1a 0
Unknown, n 1 0 1 0 0 0 0 0 0 0
  1. aPatients had events that were considered “recovering/resolving”